Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2022, with a report date of January 19, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share acquisition transactions.
| Transaction Type | Instrument | Price (GBP) | Total Volume (Shares) |
|---|---|---|---|
| Acquisition via Dividend Re-investment | Ordinary Shares (25p each) | 16.9668 | 15,205.577 |
Note: Total volume is the sum of individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of ordinary shares by eleven individuals (including the CEO and other senior executives) resulting from the re-investment of dividends paid on January 13, 2022. All transactions occurred on January 18, 2022, on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share transactions required under securities regulations.
Investor Verification Checklist
- Verify the dividend payment date of January 13, 2022, to confirm the timing of the re-investment.
- Confirm the share price of £16.9668 against market data for the London Stock Exchange on January 18, 2022.
- Review the specific roles of the PDMRs listed (e.g., CEO, President of Vaccines, Chief Commercial Officer) to assess the scope of insider participation.
- Note that this filing does not reflect the company's overall financial performance; refer to Form 20-F for annual results.